Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover

Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimental to...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer Res Treat
Main Authors: Oesterreich, Steffi, Henry, N. Lynn, Kidwell, Kelley M., Van Poznak, Catherine H., Skaar, Todd C., Dantzer, Jessica, Li, Lang, Hangartner, Thomas N., Peacock, Munro, Nguyen, Anne T., Rae, James M., Desta, Zeruesenay, Philips, Santosh, Storniolo, Anna M., Stearns, Vered, Hayes, Daniel F., Flockhart, David A.
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4807610/
https://ncbi.nlm.nih.gov/pubmed/26536870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3608-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares